Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-950P is a human pseudogene derived from the gene encoding U6 small nuclear RNA, a highly conserved and essential component of the spliceosome, the complex responsible for pre-mRNA intron removal in eukaryotic cells[3][1]. As a pseudogene, RNU6-950P does not produce functional U6 snRNA nor participate in the canonical splicing reaction, and its biological role—if any—remains uncharacterized. Pseudogenes may regulate their parental genes through competing for microRNAs or epigenetic mechanisms, but direct evidence for such activity by RNU6-950P is lacking[2]. There are many U6-related pseudogenes in vertebrate genomes resulting from the high copy number and evolutionary importance of U6 snRNA[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 950, pseudogene (RNU6-950P).